| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/27/2004 | CN1172718C Dendritic cell stimulatory factor |
| 10/27/2004 | CN1172685C Aqueous solution for parenteral absorption |
| 10/27/2004 | CN1172665C Combined medicinal preparation of sodium/hydrogen exchange-pump inhibitor and medicine for treatment of angiocardiopathy |
| 10/27/2004 | CN1172649C Process for the manufacture of liquid filled capsules |
| 10/26/2004 | US6809189 Apoptin-associating protein |
| 10/26/2004 | US6809178 Polypeptide for use in the treatment of addison's disease |
| 10/26/2004 | US6809175 Cadherin derived growth factor and its use |
| 10/26/2004 | US6809120 Protecting normal cells; overcoming drug resistance and/or toxicity |
| 10/26/2004 | US6809115 Mixture has a synergistic, weight loss effect |
| 10/26/2004 | US6809113 For therapy of arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis transplant rejection |
| 10/26/2004 | US6809112 Administering a sexually therapeutically effective amount of a compound having the formula like (5r)-5-(methylamino)-5,6-dihydro-4h-imidazo(4,5,1-ij)quinoline-2(1h)-thione |
| 10/26/2004 | US6809111 Antiinflammatory agents; analgesics |
| 10/26/2004 | US6809094 N-fused hetercyclo-1,4- or -1,5- diazabicyclo derivatives; nicotinic receptor agonists; central nervous system (cns) |
| 10/26/2004 | US6809083 Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections |
| 10/26/2004 | US6809081 Employing mycobacterium phlei-dna preserved and complexed on m. phlei cell wall; inhibiting proliferation; inducing apoptosis; potentiating antineoplastic effect |
| 10/26/2004 | US6808912 For diagnosis/therapy of inflammation, cancer, arteriosclerosis, and psoriasis |
| 10/26/2004 | US6808892 Inositolphosphoryl-ceramide (ipc) synthase; antifungal targets; drug screening; genetic engineering |
| 10/26/2004 | US6808878 Genes from the 20Q13 amplicon and their uses |
| 10/26/2004 | US6808723 Gastric acid secretion |
| 10/26/2004 | US6808719 Interior core in well containing active materials; aperture to exterior |
| 10/26/2004 | US6808710 Contacting cell expressing pd-1 with binding agent; genetic transduction of negative signal |
| 10/26/2004 | US6808705 For suppressing the proliferation of cancer cells |
| 10/26/2004 | CA2395217C Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 10/26/2004 | CA2294247C Antioxidant enhancement of therapy for hyperproliferative conditions |
| 10/26/2004 | CA2263888C Methods and compositions for the detection of cervical cancer |
| 10/21/2004 | WO2004089976A1 Method of treatment |
| 10/21/2004 | WO2004089896A1 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| 10/21/2004 | WO2004089471A2 NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| 10/21/2004 | WO2004089470A2 New amide derivatives and pharmaceutical use thereof |
| 10/21/2004 | WO2004089417A1 Drug-enclosing multilayer structure particulate and process for producing the same |
| 10/21/2004 | WO2004089416A2 Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| 10/21/2004 | WO2004089415A2 COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| 10/21/2004 | WO2004089414A2 Combinations of proton pump inhibitors or blockers with prokinetic agents |
| 10/21/2004 | WO2004089411A1 Remedy for spinal canal stenosis |
| 10/21/2004 | WO2004089407A2 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 10/21/2004 | WO2004089396A2 Anti-fungal peptidomimetics |
| 10/21/2004 | WO2004089392A1 Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
| 10/21/2004 | WO2004089380A2 Pharmaceutical use of fused 1,2,4-triazoles |
| 10/21/2004 | WO2004089379A2 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug |
| 10/21/2004 | WO2004089355A2 Compositions for treating microbial and parasitic infections in cattle and other animals |
| 10/21/2004 | WO2004089353A2 Methods for treatment of parkinson's disease |
| 10/21/2004 | WO2004089351A2 Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
| 10/21/2004 | WO2004089345A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 10/21/2004 | WO2004089341A1 Organic compounds |
| 10/21/2004 | WO2004089340A1 Pharmaceutical compositions, method, and use of formulation for the treatment and prevention of infections associated with helicobacter pylori in mammals and humans |
| 10/21/2004 | WO2004089288A2 Method of treating lower urinary tract disorders |
| 10/21/2004 | WO2004089283A2 Compositions and methods for treating viral infections |
| 10/21/2004 | WO2004089274A1 Drug packaging, or kit, or presentation facilitating self administration of drugs by patients |
| 10/21/2004 | WO2004089273A1 Chemical solution kit |
| 10/21/2004 | WO2004041250A3 Nanoparticulate fibrate formulations |
| 10/21/2004 | WO2004037186A3 Prophylactic treatment methods |
| 10/21/2004 | WO2004032844A3 Compositions and methods for treating pain |
| 10/21/2004 | WO2004028468A3 Methods and compositions for treatment of neurological disorder |
| 10/21/2004 | WO2004028451A8 β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA |
| 10/21/2004 | WO2003103614A3 Compositions for the treatment of edematous-firbrosclerotic panniculopathy |
| 10/21/2004 | WO2003100081A3 Biologically active maleamic acid derivatives with labile amide bonds |
| 10/21/2004 | WO2003096980A3 Bicyclic modulators of androgen receptor function |
| 10/21/2004 | US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS) |
| 10/21/2004 | US20040209961 Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
| 10/21/2004 | US20040209960 particularly tetrodotoxin-resistant sodium channel modulators and/or activity-dependent sodium channel modulators, including but are not limited to compounds that modulate or interact with Nav.1.8 and/or Nav1.9 channels such as Ralfinamide, Ambroxol, and Topiramate |
| 10/21/2004 | US20040209942 treating cancer and apoptosis-associated disorders using cell cycle checkpoint activation modulators; also screening for the modulators |
| 10/21/2004 | US20040209941 administering inhibitor of the renin-angiotensin system such as quinapril; for AIDS patients under retroviral therapy |
| 10/21/2004 | US20040209935 Pyrazole-derived kinase inhibitors and uses thereof |
| 10/21/2004 | US20040209934 Protein phosphate inhibitors |
| 10/21/2004 | US20040209930 Synergistic methods and compositions for treating cancer |
| 10/21/2004 | US20040209929 Fused heteroaryl carboxylic acids as PPAR agonists |
| 10/21/2004 | US20040209928 saturated 5-member heterocyclyl-substituted (hetero)aroylaminoalkyl compounds, e.g., N-(4-{3-(4-tert-butylcyclohexyl)-2-oxo-1-[4-(trifluoromethoxy)phenyl]imidazolidin-4-yl}benzoyl)-beta-alanine and N-(4-{3-(4-tert-butylphenyl)-2-oxo-1-[4-(trifluoromethoxy)phenyl]imidazolidin-4-yl}benzoyl)-beta-alanine. |
| 10/21/2004 | US20040209916 treating chronic obstructive pulmonary disease by administering a quarternary ammonium compound, and an Adenosine A2a or D2-Dopamine Receptor Agonist, PDE or norepinephrine reuptake Inhibitor, corticosteroid, or 4-hydroxy-7-[phenylethoxypropylsulphonylethylaminoethyl]benzothiazol-2(3H)-one. |
| 10/21/2004 | US20040209891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV |
| 10/21/2004 | US20040209886 nitrogen compounds such as 3-Cyano-4-[4-(cyano-phenyl-methyl)-phenylamino]-5-methyl-pyrrolo[1,2-b]pyridazine-6-carboxylic acid ethyl ester and optionally with carriers used as antiproliferative agents; enzyme inhibitors |
| 10/21/2004 | US20040209885 Combination therapy for the treatment of heart failure |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209869 Method of treating lower urinary tract disorders |
| 10/21/2004 | US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/21/2004 | US20040209861 Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209834 mouse double minute (MDM); determining the mdm2-dependent growth activity of a cell by introducing vectors for expressing a p53 polypeptide or fragment into the cell, and measuring the growth of the cell |
| 10/21/2004 | US20040209818 Immunomodulating polymers |
| 10/21/2004 | US20040209816 Treatment for diabetes |
| 10/21/2004 | US20040209813 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209799 comprises inhibitors (cytokines) of janus kinases (JAK)/signal transducers and activators of transcription (STAT) other than debromohymenialdisine and hymensialdisine; gene expression inhibition; bioassay, immunoassay, drug screening; for treatment of degenerative joint diseases such as osteoarthritis |
| 10/21/2004 | US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases |
| 10/21/2004 | US20040209319 Using high throughput assays which monitor phosphorylation and dephosphorylation of proteins to identify drugs for use as bactericides against infectious microorganisms |
| 10/21/2004 | US20040209308 Methods of assaying receptor activity and constructs useful in such methods |
| 10/21/2004 | US20040209296 Using transcription factor inhibitors and human leukocyte antigen antibodies to prevent and treatcell proliferfative disorders; genetic vaccines and antitumor agents |
| 10/21/2004 | US20040209288 Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040208935 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 10/21/2004 | US20040208923 administering a therapeutically effective amount of a pharmacologic agent that enhances learning or conditioning within 24 hours prior to conducting session of psychotherapy |
| 10/21/2004 | US20040208918 administering constituent which effects a local increase in temperature and/or an increase in blood flow of the skin in addition to the transdermally applied active substance |
| 10/21/2004 | US20040208914 Topical preparation and method for transdermal delivery and localization of therapeutic agents |
| 10/21/2004 | US20040208910 Sustained release device and method for ocular delivery of adrenergic agents |
| 10/21/2004 | US20040208908 chlorhexidine, triclosan, minocycline, bismuth nitrate, silver carbonate or silver sulfadiazine; polyvinylchloride (PVC), silicon, polytetrafluoroethylene (PTFE), silk or cotton fiber; wound dressings, sutures, catheters |
| 10/21/2004 | US20040208878 Treatment of acute lung injury, fibrosis and metastasis with antagonists of alphabetav6 |
| 10/21/2004 | US20040208874 Treating a tumor necrosis factor (TNF)- alpha mediated disease by administering TNF- alpha inhibitor and a B7gene or protein inhibitor and/or a CD28/antigen/ inhibitor; antiinflammatory agents; arthritis, autoimmune diseases, inflammatory bowel disease, psoriasis, lupus, graft versus host disease |
| 10/21/2004 | US20040208860 Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 10/21/2004 | US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents |
| 10/21/2004 | US20040208844 Products and drug delivery vehicles |
| 10/21/2004 | DE102004016947A1 Feste pharmazeutische Zusammensetzung A solid pharmaceutical composition |